The tumorigenic roles of CD38 in myeloma and other hematologic malignancies were highlighted in this review so as to gain a better insight as to the various determinants of response that can be further targeted to enhance CD38-directed antitumor mechanisms. This evidence concerns the gene CD38 and plasma cell myeloma.